Land: Irland
Språk: engelska
Källa: HPRA (Health Products Regulatory Authority)
CORYNEBACTERIUM DIPHTHERIAE CRM197 CARRIER PROTEIN ALUMINIUM PHOSPHATE
Pfizer Healthcare Ireland
0.5 Millilitre
Solution for Injection
2010-09-24
SUMMARY OF PRODUCT CHARACTERISTICS 1 NAME OF THE MEDICINAL PRODUCT Meningitec suspension for injection in pre-filled syringe Meningococcal serogroup C oligosaccharide conjugate vaccine (adsorbed). 2 QUALITATIVE AND QUANTITATIVE COMPOSITION One dose (0.5ml) contains: _Neisseria meningitidis _(strain C11) Serogroup C oligosaccharide……………… 10 micrograms Conjugated to _Corynebacterium diphtheriae_ CRM 197 carrier protein…………approximately 15 micrograms Adsorbed on aluminium phosphate … 0.125 mg Al 3+ For a full list of excipients, see section 6.1. 3 PHARMACEUTICAL FORM Suspension for injection, in pre-filled syringe. After shaking, the vaccine is a homogeneous, white suspension. 4 CLINICAL PARTICULARS 4.1 THERAPEUTIC INDICATIONS Active immunisation of children from 2 months of age, adolescents and adults for the prevention of invasive disease caused by _Neisseria meningitidis _serogroup C. The use of Meningitec should be determined on the basis of official recommendations. 4.2 POSOLOGY AND METHOD OF ADMINISTRATION POSOLOGY There are no data on the use of different Meningococcal serogroup C conjugate vaccines within the primary series or for boosting. Whenever possible, the same vaccine should be used throughout. Primary immunisation Infants up to the age of 12 months: two doses, each of 0.5 mL, the first dose given not earlier than 2 months of age and with an interval of at least 2 months between doses. Children over the age of 12 months, adolescents and adults: a single dose of 0.5 mL. The timing of the doses should be in accordance with official recommendations. Booster doses It is recommended that a booster dose should be given after completion of the primary immunisation series in infants. The timing of this dose should be in accordance with available official re Läs hela dokumentet